Every DEF 14A that BiomX Inc. (PHGE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PHGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHGE filings page.
BiomX Inc. is asking stockholders to approve several actions at a virtual special meeting on August 25, 2026. The key item is approval of issuing multiple securities to Mandragola Ltd. tied to the acquisition of Dr. Frucht Systems Ltd. (DFSL) and a $2,000,000 revolving credit line. These include 278,044 shares from a pre-funded warrant at $0.001 per share, a five-year warrant for 3,692,000 shares at $12.00, up to 325,000 shares from a $12.00 convertible note, a line-of-credit warrant for up to 2,000,000 shares at $12.00, and additional shares from convertible credit-line notes and a revenue-based bonus potentially equal to 6,250,000 shares at a $0.20 reference price. Because these issuances together exceed 20% of the 26,559,607 shares outstanding on the record date, exchange rules require stockholder approval, and existing holders face significant potential dilution.
Stockholders are also being asked to authorize one or more reverse stock splits between 1-for-5 and 1-for-20 and to reduce authorized common shares from 750,000,000 to 150,000,000, mainly to support NYSE American listing compliance and lower franchise taxes. This would be the third reverse split in roughly two years, and the company highlights strict exchange limits on cumulative split ratios and delisting risk if the price remains low. DFSL’s 2025 revenue was $292 thousand with a net loss of $119 thousand, a stockholders’ deficit of $859 thousand, and an auditor going-concern paragraph; BiomX’s prior auditor also raised going-concern doubt. Another proposal seeks to ratify Barzily & Co. as the new independent auditor and to permit adjournment of the meeting if more votes are needed.
BiomX Inc. is asking stockholders to vote at its June 26, 2026 virtual annual meeting on three items: electing Class III director Ran Shaked to a term ending at the 2029 annual meeting, approving a major amendment to its 2026 Equity Incentive Plan, and a possible adjournment.
The equity plan amendment would increase the shares of common stock reserved for awards under the 2026 Plan to 6,850,000 shares, up from 1,390,000, while shares outstanding were 11,160,153 as of June 2, 2026. The plan includes an automatic annual “Evergreen Mechanism” adding up to 4% of shares outstanding each year from 2027 through 2036, and features such as double‑trigger change‑in‑control vesting, no repricing without stockholder approval, and clawback provisions.
The proxy also details current board and committee composition, executive and director compensation for 2024–2025, equity award practices, and significant related‑party transactions, including a $3 million Series Y preferred financing with Pyu Pyu Capital LLC and stock‑ and note‑funded acquisitions of Zorro Net Ltd. and Dr. Frucht Systems Ltd. The board unanimously recommends voting “FOR” all three proposals.
BiomX Inc. has called an extraordinary special meeting on April 10, 2026 to seek stockholder approval of a new 2026 Equity Incentive Plan and a related adjournment proposal. As of the March 23, 2026 record date, 6,543,516 shares of common stock were outstanding and entitled to vote.
The 2026 Plan would authorize an initial reserve of 1,390,000 shares of common stock, replacing the 2019 omnibus plan for new grants, and includes an evergreen mechanism that can add 4% of outstanding shares each January 1 from 2027 through 2036. The plan allows options, RSUs, restricted stock, SARs, performance and other stock-based awards, with minimum one-year vesting (subject to a 5% carve-out), no repricing without stockholder approval, and double-trigger vesting on certain terminations after a change in control. The Board unanimously recommends voting “FOR” both the plan and the adjournment authority.
BiomX Inc. has called a virtual special stockholder meeting on February 25, 2026 to vote on approving a previously completed private financing and related share issuance limits under NYSE American rules.
Proposal 1 seeks authorization, for NYSE American Section 713(a) purposes, to issue common shares underlying (i) 3,300 shares of Series Y Convertible Preferred Stock, initially convertible into up to 1,650,000 common shares at $2.00 per share, and (ii) warrants to purchase up to 3,300,000 common shares at $2.00 plus 99,000 placement agent warrants at $2.50.
The Series Y Preferred Stock carries a 15% annual dividend, compounded quarterly and payable in cash or additional common shares, which can further increase the share count. The company notes that these issuances, together with any dividend and adjustment shares, could exceed 19.99% of the 1,593,516 common shares outstanding as of February 3, 2026 and may significantly dilute existing holders and pressure the stock price.
Proposal 2 would allow the board to adjourn or postpone the meeting to continue soliciting votes on Proposal 1 if necessary. The board unanimously recommends voting “FOR” both proposals.